Avenda Health, a medtech company based in Santa Monica, California has developed the Focal Therapy System. It provides AI-powered prostate cancer therapy with the aim of treating only tumorous tissues, while reducing side-effects compared with conventional therapies. The system recently received FDA breakthrough designation.
At present, there are limited treatment options for men with prostate cancer, with surgery and radiation therapy being the most commonly used approaches. However, these techniques pose significant risks for patients, including urinary and sexual dysfunction. The Avenda Focal Therapy System uses AI to design a personalized treatment plan for each patient that aims to treat only the tumor and preserve surrounding tissues.
The treatment itself occurs under local anesthesia at a urologist’s office, and involves minimally invasive laser ablation. The company compares the treatment to a lumpectomy for breast cancer treatment, and claims that it represents a significant advancement in the current standard of care.
To explore the technology a little more, Medgadget spoke with Shyam Natarajan, co-founder and CEO of Avenda Health